Default company panoramic image
04f87418 9055 4de3 9fd4 a6029688c48f

Terpenoid Therapeutics

We are the leading innovator in targeting sterol metabolism for cancer therapy, delivering products to larger pharmaceutical clients.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Coralville, IA, USA
  • Currency USD
  • Founded September 2005
  • Employees 8
  • Website

Company Summary

We are a drug discovery and development company for cancer therapies. Our product platforms stem from a near 20 year academic research program by the TTI founders focused on the novel targeting of sterol metabolism for cancer treatment. TTI’s business model is to be the key innovator of such novel therapies and to deliver these therapies to larger pharmaceutical/biotechnology companies for further development and eventual marketing to patients.


  • Default avatar
    Raymond J Hohl
    President and Chairman

    Raymond J. Hohl. President and Founder. Professor of Internal Medicine and Pharmacology and the holder of the Holden Family Chair, University of Iowa. Dr. Hohl received a BS in Biochemistry from the University of Illinois in 1978, an MD from Rush University in 1984, and a PhD in Pharmacology from Rush University in 1993. Dr. Hohl has published over sixty scientific papers that are highly related to the Terpenoid Projects.

  • Default avatar
    Stephen Collins
    Acitive Investor

    Dr. Collins career has focused on the research and clinical development of therapeutics for CNS disorders. He is currently the CEO, president and a director of NeuroTherapeutics Pharma. Prior to joining NeuroTherapeutics Pharma, he was Chief Scientific Officer & VP for Clinical Affairs of Ovation Pharmaceuticals, a CNS-focused biopharmaceutical company, growing their R&D group to a team of over 60 professionals.

  • Default avatar
    David F Wiemer
    Secretary and Director

    Dr. Wiemer is F. Wendell Miller Professor of Chemistry and Professor of Pharmacology at the University of Iowa. Dr. Wiemer received a BS in Chemistry from Marquette University in 1972 and a PhD in Organic Chemistry from the University of Illinois in 1976. Dr. Wiemer has been a professor in the Department of Chemistry at the University of Iowa since 1978, and a professor of Pharmacology since 2004. He has published ~170 scientific papers.

  • Default avatar
    Jeffrey D Neighbors
    Senior Scientist

    Dr. Neighbors received a BS in Chemistry from the University of Iowa in 1993 and a Ph.D. in Organic Chemistry from the University of Iowa in 2004. He is currently a part-time Research Scientist at the University of Iowa, and the Senior Scientist at Terpenoid Therapeutics where he directs day to day operations. Dr. Neighbors served as a Director of Terpenoid Therapeutics from 2005 to 2009. He as authored 17 scientific publications.


  • Default avatar
    Andrew Hoyne, JD, LLM Ponsinelli-Shugart St. Louis, MO
    Default avatar
    Kathy Stepp, RSM McGladrey Iowa City, IA

Previous Investors

  • Default avatar
    Iowa First Capital Fund II LP
    Default avatar
    Iowa Seed Fund I
    Default avatar
    Cedar Valley Venture Fund